以下公司为本届 ChinaBio® 投资创业论坛 - 香港的展商。
Since its founding in January, 2007, ChinaBio® LLC has rapidly launched a number of successful initiatives connecting China biotech with the world. With offices in Shanghai, Silicon Valley and San Diego, our team of industry experts is truly Helping China biotech become global biotech™.
· Conferences: ChinaBio® organizes the premier investment and partnering forums in China
· Consulting: we help big pharma, entrepreneurs and investors achieve success in China
· Accelerator: our efforts have helped early stage companies raise over $60M US in China
· Research: we have unique, in-depth data on novel technology development, clinical trial activity, VC investment, M&A/IPO activity and partnering and collaboration deals in China
· ChinaBio® Today: our newsletter focusing exclusively on China’s life science industry
Eagle IP Limited is an Intellectual Property (IP) specialty house staffed with technically and/or legally trained personnel who are well versed in IP laws and related regulations in major jurisdictions such as US, China, and Europe. We act as the bridge between the East and the West to support our client’s intellectual property rights (IPR) and technology-related activities.
ELLA CHEONG (Hong Kong and Beijing) is a boutique intellectual property (IP) consultancy and agency which specializes in trademarks, patents, designs and copyrights and we help our clients identify their IP assets and rights, secure protection over those rights and license those rights. Our chairman Ms. Ella Cheong, J.P., had been for many years precedent partner at one of Hong Kong's oldest law firms, having established its IP department which consistently received top ranking in international surveys, and also established, at the invitation of the Singapore Government, a leading IP boutique firm in Singapore now known as Ella Cheong Spruson & Ferguson. Ms. Ella Cheong was Chairman of the Intellectual Property Committee of the Law Society in Hong Kong for many years, as well as President of the Hong Kong Group of the Asian Patent Attorneys Association. She has featured in numerous publications, including “Who’s Who in the World”, “Who’s Who of Professionals”, "Guide to the World's Leading Patent Law Experts" and was listed as one of the world's top 20 trademark law practitioners in "The Best of the Best". She was nominated to the ABI International Directory of Distinguished Leadership Hall of Fame and featured in 2000 Outstanding Intellectuals of the 21st Century, as well as being awarded the Hong Kong Outstanding Women Entrepreneurs Award 2002. She was admitted to the Roll of Honour of the Law Society of Hong Kong in 2004 and received Matsushita’s Panasonic Gold Award of Merit for Contribution to Protection of IP Rights 2004.
Filligent is a Hong Kong biotech company that develops advanced and affordable ‘intelligent filtration’ technologies designed to combat the transmission or initiation of diseases. Using biochemistry at the molecular level, our proprietary technologies seek out dangerous pathogens and chemicals and then kill or inactivate them before they enter the human body. Our patented technologies are able to select and filter out dangerous agents from the air, water, and from off surfaces – including the human skin. Filligent provides ordinary people with affordable and advanced protective devices against infectious or other diseases. Filligent gives people Health Choices.
Hong Kong Science and Technology Parks Corporation (HKSTP) is a statutory body set up by the Government of the Hong Kong SAR to promote and facilitate the transformation of Hong Kong into Asia’s hub for technology innovation. The Corporation supports a number of technology industries engaging in cutting-edge research and development, including the Life Science and Biotechnology industries, and offers a comprehensive range of facilities and services to address the needs of companies at various stages of development. The Hong Kong Science Park, a striking 22-hectare R&D campus along the waterfront, is a key component of the Corporation. With the recent completion of the biotechnology laboratory buildings and the biotechnology SME centre with modular wet labs, the Park stands ready to support a variety of Life Science related sectors including Medical Devices & Diagnostics, Chemical & Biological Therapeutics, Molecular Biology Instrumentation, Tools & Reagents, Chinese and Herbal Medicine, Regenerative Medicine and Bioinformatics. Partner companies can take advantage of the Technology Support Centre with shared R&D facilities and equipments, as well as enjoy the benefits of technological clustering.
Merck is a global research-driven pharmaceutical company dedicated to putting patients first. We discover, develop, manufacture, and market vaccines and medicines to address unmet medical needs, directly and through alliances with our partners. Our mission is to provide people with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs. With approximately 60,000 employees, Merck conducts research at 9 major research centers worldwide, manufactures products in 28 facilities, and operates in more than 140 countries.
Morrison & Foerster’s Life Sciences Practice is comprised of more than 160 attorneys dedicated to serving life sciences companies, research institutions, and the venture capital funds and investments banks that finance them. Morrison & Foerster is a global law firm offering services in corporate finance, mergers & acquisitions, patent strategy and prosecution, collaborations and licensing agreements, trade secret litigation and counseling, employment and labor, and commercial, intellectual property and securities litigation. With offices in Shanghai, Beijing, and Hong Kong, as well as Tokyo, Europe and the United States, we are uniquely positioned to assist life sciences entities around the world.
PLA Liver Disease Research Center
PLA Liver Disease Research Center, PLA 458 Hospital, China. Since our founding in 1978, the PLA Liver Disease Research Center run by PLA 458 Hospital, has become well known for its skill and vision on research and development of new drugs or therapeutics for management of the liver disease due to hepatitis B virus (HBV) infection in China. In the 1990s of last century, Hepatocyte growth promoting factors (pHGF), a biochemical new drug approved by State Public Health Ministry, is the first product we prepared and applied for management of fulminant hepatitis in China. In the new century, we have focused on research & development of anti-HBV therapeutics by means of immuno-modulation in the field of biotech and life science. Dual-plasmid therapeutic HBV DNA vaccine is the first investigative new drug (IND) that has been approved by SFDA for its clinical trial entry. For the drug efficacy evaluation platform built-up, we have generated the HBV transgenic mouse model and applied it in new antiviral drug preclinical study for a number of bio-companies domestically. Both projects have been brought into the national long-term research program for management of HBV infection.